anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Naproxen Sodium
Trial phase: Phase 4
SMILES: COc1ccc2cc(C(C)C(=O)[O-])ccc2c1.[Na+]
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 166
Group description: Subjects received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
Eligibility criteria:
Inclusion Criteria:

Healthy, ambulatory, male or female volunteers 16-40 years of age;
Body mass index 18.0 to 30.0 kg/m^2 inclusive;
Scheduled to undergo surgical removal of at least 2 mandibular partial or full bony impacted third molars. Up to two maxillary third molars may be removed regardless of impaction level. Supernumerary teeth present may also be removed at the discretion of the oral surgeon;
Mandibular molars must demonstrate modified Demirjian root classification stage D, E, F, G or H;

Exclusion Criteria:

History of hypersensitivity to naproxen sodium, ibuprofen, nonsteroidal anti-inflammatory drugs (NSAIDS), aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the investigational products;
Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;
Relevant concomitant disease such as asthma (exercise induced asthma is permitted)
Intervention: Ibuprofen
Trial phase: Phase 4
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 166
Group description: Subjects received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
Eligibility criteria:
Inclusion Criteria:

Healthy, ambulatory, male or female volunteers 16-40 years of age;
Body mass index 18.0 to 30.0 kg/m^2 inclusive;
Scheduled to undergo surgical removal of at least 2 mandibular partial or full bony impacted third molars. Up to two maxillary third molars may be removed regardless of impaction level. Supernumerary teeth present may also be removed at the discretion of the oral surgeon;
Mandibular molars must demonstrate modified Demirjian root classification stage D, E, F, G or H;

Exclusion Criteria:

History of hypersensitivity to naproxen sodium, ibuprofen, nonsteroidal anti-inflammatory drugs (NSAIDS), aspirin, similar pharmacological agents, local anesthetics, rescue medication or components of the investigational products;
Evidence or history of clinically significant (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or malignancies within the last 5 years;
Relevant concomitant disease such as asthma (exercise induced asthma is permitted)
Intervention: Hydrocodone Bitartrate Acetaminophen
Trial phase: Phase 3
SMILES: CC(=O)Nc1ccc(O)cc1.COc1ccc2c3c1OC1C(=O)CCC4C(C2)N(C)CCC314.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 97
Group description: This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.

If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control.

Norco: Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
Eligibility criteria:
Inclusion Criteria:

Patients undergoing one of the following outpatient procedure:

Septoplasty
Unilateral or Bilateral Functional endoscopic sinus surgery
Tympanomastoidectomy
Tympanoplasty
Total or Partial Thyroidectomy
Parathyroidectomy
Parotidectomy.
Age >18 years and < 89 years

Exclusion Criteria:

Age < 18 years or > 89 years
Post operative hospital admission
Allergy to Hydrocodone
Allergy or contraindication to Ibuprofen or NSAIDs
Pregnancy
Hepatic disease
Chronic kidney disease
Sickle cell anemia
Intervention: Ibuprofen
Trial phase: Phase 3
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 88
Group description: This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.

If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control.

Ibuprofen: Ibuprofen as first line therapy every 6 hours as needed for pain control
Eligibility criteria:
Inclusion Criteria:

Patients undergoing one of the following outpatient procedure:

Septoplasty
Unilateral or Bilateral Functional endoscopic sinus surgery
Tympanomastoidectomy
Tympanoplasty
Total or Partial Thyroidectomy
Parathyroidectomy
Parotidectomy.
Age >18 years and < 89 years

Exclusion Criteria:

Age < 18 years or > 89 years
Post operative hospital admission
Allergy to Hydrocodone
Allergy or contraindication to Ibuprofen or NSAIDs
Pregnancy
Hepatic disease
Chronic kidney disease
Sickle cell anemia
Intervention: Racivir
Trial phase: Phase 3
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 86
Group description: B/F/TAF (50/200/25 mg) FDC tablet once daily, without regard to food for at least 96 weeks.
Eligibility criteria:
Key Inclusion Criteria:

Currently receiving an antiretroviral regimen of E/C/F/TAF FDC (or emtricitabine [FTC]/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826 [NCT02616783]) for ≥ 3 months
Documented plasma HIV-1 ribonucleic acid (RNA) < 50 copies/mL during treatment with E/C/F/TAF (or FTC/TDF + 3rd agent if currently or previously participated in Study GS-US-292-1826 [NCT02616783]) for the last 2 visits preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)
Adequate renal function, an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance

Key Exclusion Criteria:

An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening
Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding)
Current alcohol or substance use judged by the investigator to potentially interfere with participant study compliance

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.
Intervention: Lasmiditan
Trial phase: Phase 1
ATC code: N02CC08
SMILES: CN1CCC(C(=O)c2cccc(NC(=O)c3c(F)cc(F)cc3F)n2)CC1
Sex: All
Age groups: Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 35
Group description: Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
Eligibility criteria:
Inclusion Criteria:

Are overtly healthy males or females, as determined through medical history and physical examination
Have a body mass index (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²), inclusive, at the time of screening.

Exclusion Criteria:

Have known allergies to lasmiditan, related compounds, or any components of the formulation.
Are persons who have previously received lasmiditan.
Have a history of, or electrocardiogram (ECG) findings of, clinically significant bradycardia, heart block, tachy or brady arrhythmias, or have any other abnormality in the 12-lead ECG that, in the opinion of the investigator, increases the risks associated with participating in the study.
Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data. appendectomy, splenectomy, and cholecystectomy are considered as acceptable.
Show a history of central nervous system (CNS) conditions such as strokes, transient ischemic attacks, significant head trauma, seizures, CNS infections, migraines, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increase the risk of participating in the study.
Show evidence of active renal disease (e.g. diabetic renal disease, polycystic kidney disease) or estimated glomerular filtration rate <60 milliliters per minute per 1.73 meter squared (mL/min/m²).
Have a history of syncope, presyncopy, uncontrolled vertigo, postural dizziness, or at risk for falls, as judged to be clinically significant by the investigator.
Intervention: Humalog
Trial phase: Phase 1
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CCCCN)C(=O)N3CCCC3C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: A single dose of 15 U insulin lispro (Humalog) administered SC in one of two study periods.
Eligibility criteria:
Inclusion Criteria:

Are Japanese male or female participant with a diagnosis of T1DM, based on the World Health Organization classification, for at least 1 year prior to screening
Have a body mass index (BMI) of 18.5 to 30.0 kilograms per square meter (kg/m²)
Have a glycated hemoglobin <9.0% at screening

Exclusion Criteria:

Have, except for current regimen of insulin therapy and concomitant medication(s), regular use of or intended use of any over-the-counter or prescription medications or nutritional supplements that treat hyperglycemia or insulin resistance or that promote weight loss within 14 days before dosing
Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled glucocorticoid therapy (excluding topical, intra-articular, and intraocular preparations), or have received such therapy within the 4 weeks before screening
Have a history of renal impairment (exclusion only if estimated glomerular filtration rate [GFR] <60 milliliters/minute/1.73 square meters [GFR is estimated according to a formula recommended by the Japanese Society of Nephrology]), or have a serum creatinine level ≥126 micromoles per liter (μmol/L) (>1.42 milligrams per deciliter [mg/dL]) (male) or ≥111 μmol/L (>1.25 mg/dL) (female)
Have a history of deep vein thrombosis of the leg, or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children), as determined by the investigator
Have proliferative retinopathy or maculopathy and/or severe neuropathy; in particular, autonomic neuropathy, as determined by the investigator based on a recent (<1.5 years) ophthalmologic examination
Have had any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening, as determined by the investigator
Require daily insulin treatment >1.5 units per kilogram (U/kg)
Intervention: Fenebrutinib
Trial phase: Phase 2
SMILES: C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 160
Group description: Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
Eligibility criteria:
Inclusion Criteria:

Able to comply with the study protocol, in the investigator's judgment
Completion of Study GA30044 up to 48 weeks
Acceptable safety and tolerability during Study GA30044 as determined by the investigator

Exclusion Criteria:

Met protocol-defined treatment-stopping criteria during Study GA30044
An adverse event in Study GA30044 that required permanent discontinuation of study drug
In the opinion of the investigator, any new, significant, uncontrolled comorbidity or new clinical manifestation (related to SLE or not) that requires medications not allowed in this protocol; or could put the participant at undue risk from a safety perspective
Any uncontrolled or clinically significant laboratory abnormality that would affect safety, interpretation of study data, or the participant's participation in the study in the opinion of the investigator in consultation with the Medical Monitor
Intervention: Bupivacaine
Trial phase: Phase 2 | Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.
Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.
After QLB is placed, patients will have THA under spinal anesthesia.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing total hip arthroplasty
Adults 18 years of age and older
Patients with an American Society of Anesthesiology (ASA) physical status classification of I, II or III

Exclusion Criteria:

Patients with ASA physical status classification other than I, II, or III
Patients with allergies/intolerances to local anesthetic
Patients with pre-existing neurologic or anatomic deficits in the lower extremity on the side of the surgical site
Patients with coexisting coagulopathy
Patients that are pharmacologically anticoagulated will be excluded if placement of peripheral nerve block would be contraindicated according to ASRA (American Society for Regional Anesthesia) guidelines or if spinal anesthesia would be contraindicated according to guidelines
Intervention: Opioid
Trial phase: Phase 2 | Phase 3
SMILES: CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.CCOC(=O)C1(c2ccccc2)CCN(C)CC1.COc1ccc2c3c1OC1C(=O)CCC4(O)C(C2)N(C)CCC314
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.
Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected.

Standard of Care: This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing total hip arthroplasty
Adults 18 years of age and older
Patients with an American Society of Anesthesiology (ASA) physical status classification of I, II or III

Exclusion Criteria:

Patients with ASA physical status classification other than I, II, or III
Patients with allergies/intolerances to local anesthetic
Patients with pre-existing neurologic or anatomic deficits in the lower extremity on the side of the surgical site
Patients with coexisting coagulopathy
Patients that are pharmacologically anticoagulated will be excluded if placement of peripheral nerve block would be contraindicated according to ASRA (American Society for Regional Anesthesia) guidelines or if spinal anesthesia would be contraindicated according to guidelines
Intervention: Aripiprazole
Trial phase: Phase 4
ATC code: N05AX12
SMILES: O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention

Abilify Maintena: Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.

Customized Adherence Enhancement (CAE): CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
Eligibility criteria:
Inclusion Criteria:

Individuals age 18 and older with BD Type 1 or 2 as confirmed by the Mini International Psychiatric Inventory (MINI).
Known to have medication treatment adherence problems as identified by the Treatment Routines Questionnaire (TRQ, 20% or more missed medications in past week or past month)
Screening the Brief Psychiatric Rating Scale (BPRS) score of ≥ 36
Ability to be rated on psychiatric rating scales.
Willingness to take long-acting injectable antipsychotic medication (LAI)
Currently in treatment or scheduled to receive treatment at a Community Mental Health Clinic (CMHC) or other clinical setting able to provide mental health care during and after study participation
Able to provide written, informed consent to study participation.

Exclusion Criteria:

Individuals on LAI immediately prior to study enrollment.
Individuals with known intolerance or resistance to either oral aripiprazole or LAI formulation of aripiprazole
Prior or current treatment with clozapine
Medical condition or illness, which in the opinion of the research psychiatrist, would interfere with the patient's ability to participate in the trial
Physical dependence on substances (alcohol or illicit drugs) likely to lead to withdrawal reaction during the course of the study in the clinical opinion of the treated research psychiatrist
Immediate risk of harm to self or others
Female who is currently pregnant or breastfeeding
Intervention: Risedronate sodium
Trial phase: Phase 4
SMILES: O=P([O-])(O)C(O)(Cc1cccnc1)P(=O)(O)O.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 11
Group description: Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.

Risedronate Sodium 150 MG: Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
Eligibility criteria:
Inclusion Criteria

Subjects planning a sleeve gastrectomy procedure
40-79 yrs of age
Willingness to provide informed consent
Agreement to all study procedures and assessments

Exclusion Criteria

Age <40 years
Baseline weight >450 pounds
Chronic anti-reflux treatment
History of medical disorders known to affect bone metabolism
Use of bone-active medications
Known allergy to Risedronate
Intervention: Chlorhexidine
Trial phase: Phase 4
ATC code: A01AB03 | B05CA02 | D08AC02 | D08AC52 | D09AA12 | R02AA05 | S01AX09 | S02AA09 | S03AA04
SMILES: N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 94
Group description: Chlorhexidine: Chlorhexidine preparation solutions
Eligibility criteria:
Inclusion Criteria:

Undergoing total vaginal, laparoscopic assisted vaginal, total laparoscopic, or robotic-assisted laparoscopic hysterectomy by a physician at Cincinnati Urogynecology Associates or Tri-State Gynecology Oncology TriHealth Inc.
Concomitant procedures such as vaginal vault suspension, suburethral sling, cystoscopy, enterocele repair, anterior or posterior colporrhaphy, bilateral salpingectomy or salpingooophorectomy, staging procedures, lymph node sampling and other indicated procedures will be included
English speaking
Ability to provide consent

Exclusion Criteria:

Unwillingness to participate in the study
Non English speaking
Patients that do not undergo a hysterectomy
Reported allergy to iodine or chlorhexidine preparation solutions
Patients undergoing planned debulking surgery for ovarian, fallopian tube or primary peritoneal cancers
Current infection necessitating hysterectomy
Active sepsis, pelvic abscess or pelvic inflammatory disease
Intervention: Iodine
Trial phase: Phase 4
ATC code: D08AG03
SMILES: II
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 94
Group description: Iodine: Iodine-based preparation solutions
Eligibility criteria:
Inclusion Criteria:

Undergoing total vaginal, laparoscopic assisted vaginal, total laparoscopic, or robotic-assisted laparoscopic hysterectomy by a physician at Cincinnati Urogynecology Associates or Tri-State Gynecology Oncology TriHealth Inc.
Concomitant procedures such as vaginal vault suspension, suburethral sling, cystoscopy, enterocele repair, anterior or posterior colporrhaphy, bilateral salpingectomy or salpingooophorectomy, staging procedures, lymph node sampling and other indicated procedures will be included
English speaking
Ability to provide consent

Exclusion Criteria:

Unwillingness to participate in the study
Non English speaking
Patients that do not undergo a hysterectomy
Reported allergy to iodine or chlorhexidine preparation solutions
Patients undergoing planned debulking surgery for ovarian, fallopian tube or primary peritoneal cancers
Current infection necessitating hysterectomy
Active sepsis, pelvic abscess or pelvic inflammatory disease
Intervention: Lidocaine
Trial phase: Early Phase 1
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 34
Group description: 2% Lidocaine: 2% Lidocaine (with epinephrine, bicarbonate, and fentanyl) using a combined spinal-epidural (CSE)
Eligibility criteria:
Inclusion Criteria:

≥ 18 years of age for the mother
Singleton pregnancy
Gestation > 36 weeks
American Society of Anesthesiologist (ASA) class II
Provides written consent
Infant of mother

Exclusion Criteria:

Patient refusal
Non-elective or urgent/emergent cesarean sections
ASA class III or above
Unable to understand English
Significant back surgery or scoliosis
Known fetal abnormality
Weight > 120 kg
Height < 150 cm
Allergy to local anesthetics
Concurrent use of sulfonamides